Medicine School of Nankai University, Tianjin, China.
Department of Endocrinology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Front Endocrinol (Lausanne). 2022 Aug 5;13:949003. doi: 10.3389/fendo.2022.949003. eCollection 2022.
To perform a systematic review and meta-analysis of interferon and endocrine side effects, including their incidence, evaluation, and management.
PubMed was searched through March 7th, 2021, by 2 authors independently (LH Wang and H Zhao). Early phase I/II, phase III experimental trials, prospective and retrospective observational studies were included. Stata 16.0 (StataCorp LLC, 16.0) was the main statistical software for meta-analysis. The weighted incidence and risk ratio were estimated for primary thyroid disease and diabetes mellitus.
A total of 108 studies involving 46265 patients were included. Hypothyroidism was the most common thyroid disorder, followed by hyperthyroidism. IFN α+RBV treated patients experienced hypothyroidism in 7.8% (95%CI, 5.9-9.9), which was higher than IFN α (5.2%; 95%CI, 3.7-6.8) and IFN β (7.0%; 95%CI, 0.06-23.92). IFN α+RBV treated patients experienced hyperthyroidism in 5.0% (95%CI, 3.6-6.5), which was higher than IFN α (3.5%; 95%CI, 2.5-4.8) and IFN β (3.4%; 95%CI, 0.9-7.5). The summary estimated incidence of painless thyroiditis was 5.8% (95%CI, 2.8-9.8) for IFN α, and 3.5% (95%CI,1.9-5.5) for IFN α+RBV. The summary estimated incidence of diabetes was 1.4% (95%CI, 0.3-3.1) for IFN, 0.55% (95%CI, 0.05-1.57) for IFN α, 3.3% (95%CI,1.1-6.6) for IFN α+RBV.
Our meta-analysis shows a high incidence of endocrine adverse events provoked by IFN, further reinforced by combined RBV treatment.
https://www.crd.york.ac.uk/prospero/, identifier CRD42022334131.
对干扰素和内分泌副作用进行系统回顾和荟萃分析，包括其发生率、评估和管理。
由 2 位作者（LH 王和 H 赵）于 2021 年 3 月 7 日之前独立检索 PubMed。纳入早期 I/II 期、III 期实验性试验、前瞻性和回顾性观察性研究。Stata 16.0（StataCorp LLC，16.0）是主要的荟萃分析统计软件。对原发性甲状腺疾病和糖尿病的发生率和风险比进行了加权估计。
共纳入 108 项研究，涉及 46265 例患者。甲状腺功能减退症是最常见的甲状腺疾病，其次是甲状腺功能亢进症。IFN α+RBV 治疗患者的甲状腺功能减退症发生率为 7.8%（95%CI，5.9-9.9），高于 IFN α（5.2%；95%CI，3.7-6.8）和 IFN β（7.0%；95%CI，0.06-23.92）。IFN α+RBV 治疗患者的甲状腺功能亢进症发生率为 5.0%（95%CI，3.6-6.5），高于 IFN α（3.5%；95%CI，2.5-4.8）和 IFN β（3.4%；95%CI，0.9-7.5）。IFN α 汇总估计的无痛性甲状腺炎发生率为 5.8%（95%CI，2.8-9.8），IFN α+RBV 为 3.5%（95%CI，1.9-5.5）。IFN 汇总估计的糖尿病发生率为 1.4%（95%CI，0.3-3.1），IFN α 为 0.55%（95%CI，0.05-1.57），IFN α+RBV 为 3.3%（95%CI，1.1-6.6）。
我们的荟萃分析表明，干扰素引起的内分泌不良事件发生率较高，联合 RBV 治疗进一步加强了这一结果。
https://www.crd.york.ac.uk/prospero/，标识符 CRD42022334131。
